Study using autologous stem cells to treat MS gets FDA OK

08/19/2013 | BioSpectrum Asia · Medical News Today

The FDA has granted Tisch MS Research Center of New York investigational new drug approval to launch a Phase I study to test the use of neural stem cells derived from a patient's own bone marrow to treat multiple sclerosis. "To my knowledge, this is the first FDA-approved stem cell trial in the U.S. to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment," lead researcher Dr. Saud Sadiq said.

View Full Article in:

BioSpectrum Asia · Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC